Aims-To determine the expression of intercellular adhesion molecule 1 and 2 (ICAM 1 and 2) in transitional cell carcinoma cells before and after immunotherapy with Calmette-Guerin bacillus (BCG).
(BCG).
Methods-Frozen sections from 22 untreated bladder carcinomas were immunohistochemically examined with monoclonal antibodies to ICAM 1 and 2. Urinary cytospin slides were made for six patients for each of the six clinical instillations which constitute a therapeutic course. These slides were also stained for ICAM 1 and for leucocyte function associated antigen 1 (LFA 1). Results-Bladder cancer cells did not essentially express either ICAM 1 or 2, but cells in the stromal areas surrounding tumour expressed both these antigens. After repeated instillations of BCG organisms ICAM 1 positive normal and neoplastic epithelial cells were observed in the urine. Cells obtained from the first three instillations expressed lower densities of ICAM 1 than those from the later instillations. Many neutrophils expressing LFA-1 and some lymphocytes were also noted in the cytospin slides and some of these were conjugated to tumour cells expressing ICAM 1. Six months after treatment a single maintenance dose of BCG induced ICAM 1 expression. Conclusion-Untreated superficial bladder carcinoma cells do not express ICAM 1 or 2, but these important immunological molecules were expressed in the stromal areas oftissue. Importantly, neoplastic cells in the urine expressed ICAM 1 after immunotherapy. This molecule can render bladder tumour cells vulnerable to non-antigen specific cytotoxicity mediated by activated lymphocytes.
Local immunotherapy with intravesical BCG (Calmette Guerin bacillus) now has a major role in the treatment and prophylaxis of superficial bladder cancer. ' The exact mechanisms of action are poorly understood, but findings indicate that an effective host mounted immune response is generated.2 Such a response is characterised by infiltration of immunologically active cells into the bladder wall3 and the secretion in the urine of interleukin 1 (IL 1), IL 2, tumour necrosis factor a (TNFa) and interferon y (IFNy)." Furthermore, the neo-expression of mixed histocompatibility complex (MHC) class II molecules by the tumour cells has been reported,7 though the in vivo relevance of this is unknown.
In vitro we have shown that therapeutically achievable urine concentrations of IFNy can induce and increase the expression of both MHC class II and intercellular adhesion molecule 1 (ICAM 1, CD54) on bladder tumour cell lines.8-11 ICAM 1 is a cytokine inducible adhesion molecule (molecular weight 95 kilodaltons) and is one of three known counterreceptors for the major fl2 integrin, leucocyte function-associated antigen 1 (LFA 1, CD1 la/CD 18). 2 l The interaction between ICAM and LFA 1 is important for several basic immunological processes, including antigen presentation to T lymphocytes and the extravasation of leucocytes through activated vascular endothelium.15 LFA 1 dependent functions are tightly regulated to prevent erroneous conjugation with other cells.'658
Our earlier studies have implicated ICAM 1 in the interaction between activated lymphocytes and bladder tumour cells.9 Following such LFA 1/ICAM dependent conjugation events, the activated effector cell was able to mediate the eventual destruction of tumour cells. '9 In these studies antibodies to either ICAM 1 or LFA 1 negated the conjugation of effector cells with tumour targets and the subsequent delivery of "lethal-hit".920 If such conjugation were to occur in vivo, after instillation of BCG organisms into the bladder then ICAM 1 expression on the tumour cell may well be required. We therefore investigated the constitutive expression of ICAM 1 and ICAM 2 on bladder tumour biopsy specimens from untreated patients and on urinary cytospin preparations obtained after intravesical BCG treatment of this malignancy.
Methods
Biopsy material from patients with histologically confirmed transitional cell carcinoma of the bladder was taken and stored in liquid nitrogen for further processing. Patients were selected to undergo immunotherapy with intravesical instillations of BCG. Non-invasive urinary cytospin specimens were obtained from these patients during each week of, and after, treatment. Patients were followed up with check cytoscopies, biopsies, and urine cytology performed at three monthly intervals. After the first six months their initial response to treatment was assessed and correlated with immunohistochemical findings. Patients who were free of disease at this point received a single dose of BCG as maintenance treat-30ackson, Alexandroff, McIntyre, Esuvaranathan, J7ames, Chisholm ment. Patients whose disease had relapsed received cysto-urethectomy.
Evans (Glaxo) high strength percutaneous BCG in lyophilised form was used. Twenty ampoules containing a total of 1-5 x 109 cfu was mixed with 50 ml of physiological saline and instilled into the bladder through a urinary catheter which was subsequently removed. The patients retained the suspension for two hours, during which they were asked to lay on their beds turning from supine to lateral to prone positions at 15 minute intervals in order to expose all surfaces of the bladder to the suspension. Instillations were repeated weekly for six weeks.
PREPARATION OF FROZEN SECTIONS AND URINARY CYTOSPIN SLIDES
Frozen sections were cut to 5 ,um thickness at -25°C and mounted on to poly-L-lysine coated glass slides for staining. Cytospins were prepared as follows: freshly voided midstream urine was centrifuged at 1500 rpm for five minutes. The pellet was resuspended in a few millilitres of serum-enriched RPMI 1640 (Gibco, Paisley, UK). Using a cytocentrifuge, 200 ,ul of cell suspension was spun at 700 rpm for eight minutes against poly-L-lysine coated glass slides. All specimens were air dried for 20 minutes, then fixed in acetone for a further 20 the third instillation three patients had high levels of ICAM 1 expression. Malignant and normal epithelial cells obtained from the later instillations, however," from all patients showed that more than 50% of these cell types expressed ICAM 1 (table 2, fig 2) . A significance value of p < 0 001 was obtained when the difference in ICAM 1 expression on cells obtained after one instillation of BCG and six instillations were compared. Tumour cells were not stained for ICAM 2 expression after BCG treatment as ICAM 2 is not essentially expressed and is known not to be a cytokine inducible gene.
MANTENANCE TREATMENT
The expression of ICAM 1 was maintained for at least six months after the final instillation of BCG. After six months patients who had undergone a complete response to immunotherapy (as judged by cystoscopic examination) were given a single instillation of BCG organisms, termed "maintenance." The expression of ICAM 1 on normal epithelial cells shed into the urine was also studied using immunohistochemistry. Unlike the first course of treatment, where expression of ICAM 1 was initially absent, over 50% of cells obtained after the maintenance course were positive for ICAM 1 expression. The data showing first response to BCG and "maintenance" are summarised in 
